Cargando…

ESR1 mutations in breast cancer

Detalles Bibliográficos
Autores principales:	Clatot, Florian, Augusto, Laetitia, Di Fiore, Frédéric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310651/ https://www.ncbi.nlm.nih.gov/pubmed/28130553 http://dx.doi.org/10.18632/aging.101165

Ejemplares similares

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients
por: Allouchery, Violette, et al.
Publicado: (2018)

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
por: Clatot, Florian, et al.
Publicado: (2016)

Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma
por: Drouyer, Aurélien, et al.
Publicado: (2023)

ESR1 mutations in metastatic lobular breast cancer patients
por: Desmedt, Christine, et al.
Publicado: (2019)

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer
por: Clatot, Florian, et al.
Publicado: (2020)

Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer
por: Zhu, Wenzhen, et al.
Publicado: (2020)

ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer
por: Carausu, Marcela, et al.
Publicado: (2019)

ESR1 ligand binding domain mutations in hormone-resistant breast cancer
por: Toy, Weiyi, et al.
Publicado: (2013)

Prevalence of Estrogen Receptor Alpha (ESR1) Somatic Mutations in Breast Cancer
por: Kinslow, Connor J, et al.
Publicado: (2022)

Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients
por: Allouchery, Violette, et al.
Publicado: (2021)

Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
por: Reinert, Tomas, et al.
Publicado: (2017)

Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer
por: Kuang, Yanan, et al.
Publicado: (2018)

Targeting ESR1 mutation–induced transcriptional addiction in breast cancer with BET inhibition
por: Udden, Sm N., et al.
Publicado: (2022)

ESR1 mutations: Pièce de résistance
por: Button, Berry, et al.
Publicado: (2016)

Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy
por: Lambertini, Matteo, et al.
Publicado: (2019)

Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients
por: Niu, Jiaxin, et al.
Publicado: (2015)

Currently Applied Molecular Assays for Identifying ESR1 Mutations in Patients with Advanced Breast Cancer
por: Lee, Nuri, et al.
Publicado: (2020)

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
por: Brett, Jamie O., et al.
Publicado: (2021)

Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
por: Li, Zheqi, et al.
Publicado: (2022)

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models
por: Bahreini, Amir, et al.
Publicado: (2017)

Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines
por: Sappok, Anne, et al.
Publicado: (2011)

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
por: De Santo, Irene, et al.
Publicado: (2019)

ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
por: Martin, Lesley-Ann, et al.
Publicado: (2017)

Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis
por: Zhang, Kai, et al.
Publicado: (2018)

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations
por: Lopez-Knowles, Elena, et al.
Publicado: (2018)

Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer
por: Dahlgren, Malin, et al.
Publicado: (2021)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
por: Spoerke, Jill M., et al.
Publicado: (2016)

Detection of Ultra-Rare ESR1 Mutations in Primary Breast Cancer Using LNA-Clamp ddPCR
por: Hashimoto, Yoko, et al.
Publicado: (2023)

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1
por: Berger, Frédérique, et al.
Publicado: (2022)

ESR1 alterations and metastasis in estrogen receptor positive breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2019)

Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

TERT Promoter Alterations in Glioblastoma: A Systematic Review
por: Olympios, Nathalie, et al.
Publicado: (2021)

ESR1 and ESR2 genotypes and the age at menarche in idiopathic scoliosis
por: Janusz, Piotr, et al.
Publicado: (2014)

Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
por: Harrod, A, et al.
Publicado: (2017)

Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

The ESR Patient Advisory Group (ESR-PAG)
Publicado: (2015)

The predictive ability of plasma ESR1 mutations for the efficacy of endocrine therapy in hormone-receptor-positive advanced breast cancer
por: Du, Yangfan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_aj545l6f9034ps39vo70oq4u3d